Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Aug 2023 · 1 min read
In brief
In brief
This retrospective study of 30 pediatric patients with relapsed/refractory hepatoblastoma examines treatment strategies and outcomes, finding that cisplatin retreatment may offer survival benefits. The analysis includes molecular profiling showing frequent CTNNB1 mutations and describes relapse patterns primarily involving lung and liver sites.
Written by the GCMD Library team from the article.
Statements in this article
Hepatoblastoma is the most common liver malignancy in children.
There is no standard of care for management of relapsed/refractory hepatoblastoma.
The median age at initial hepatoblastoma diagnosis was 19.5 months (range 3-169 months).
The median age at time of first relapse was 32.5 months (range 12-194 months).
63% of subjects were male, 70% Caucasian, and 13% were born premature.
Three subjects had a known cancer predisposition syndrome.
Eight patients had refractory disease while 22 patients had relapsed disease.
Average time from initial diagnosis to relapse or progression was 12.5 months.
Average alpha-fetoprotein at initial diagnosis was 601,203 ng/mL (range 121-2,287,251 ng/mL).
Average alpha-fetoprotein at relapse was 12,261 ng/mL (range 2.8-201,000 ng/mL).
The most common mutations in patients with tumor sequencing were in CTNNB1 (13 of 17 patients) and NRF2 (4 of 17 patients).
First relapse sites were lungs (n=12), liver (n=11), and both (n=6).
More than one relapse or progression occurred in 47% of subjects, with 6 having 3 or more relapses.